Skip to main
PVLA

PVLA Stock Forecast & Price Target

PVLA Analyst Ratings

Based on 14 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Palvella Therapeutics is a clinical-stage biopharmaceutical company with a strong focus on developing and commercializing novel therapies for rare skin diseases and vascular malformations. Its lead asset, QTORIN rapamycin, has already shown promising results in clinical trials for multiple indications, including microcystic lymphatic malformations and cutaneous venous malformations. With an experienced management team and a potential for significant market penetration in these niche markets, Palvella has a strong potential for growth and success.

Bears say

Palvella Therapeutics is a biopharmaceutical company with a new and unproven technology for rare genetic skin diseases. While their lead candidate has shown promising results, concerns about legal challenges, funding needs, and regulatory and commercial risks may negatively impact their success. These factors, along with the company’s current valuation and global expansion plans, make it a risky investment choice at this time.

PVLA has been analyzed by 14 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Palvella Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Palvella Therapeutics Inc (PVLA) Forecast

Analysts have given PVLA a Strong Buy based on their latest research and market trends.

According to 14 analysts, PVLA has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $190.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $190.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Palvella Therapeutics Inc (PVLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.